Together, these data provide evidence that both miR‐125b inhibition and RIG‐I‐mediated activation enhanced the anti‐tumour efficacy of 3p‐125b‐ASO in an orthotopic breast cancer model. This evidence concerns the gene RIGI and breast carcinoma.